Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio (NASDAQ: BLTE) will give an oral presentation on May 1, 2026 at the Retinal Therapeutics Innovation Summit in Denver covering topline Phase 3 DRAGON results for tinlarebant in Stargardt disease type 1.
According to the company, tinlarebant showed a 35.7% reduction in atrophic retinal lesion growth versus placebo and demonstrated a strong safety profile. Presentation details: May 1, 2026, 10:55-11:10 a.m. MDT, session "Small Molecules to the Rescue," presenter Nathan L. Mata, Ph.D.
Belite Bio (NASDAQ: BLTE) will participate in four investor conferences between April 28 and May 26, 2026, including Deutsche Bank ADR Virtual, BofA Securities Health Care, H.C. Wainwright BioConnect Nasdaq, and Stifel Virtual Ophthalmology Forum.
Webcasts are available under Events on the company investor site and replays will be archived for 90 days after each presentation.
Belite Bio (NASDAQ: BLTE) has initiated a rolling submission of a New Drug Application to the FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1 (STGD1). The FDA previously granted Breakthrough Therapy Designation and approved the rolling submission.
The company expects to complete the NDA rolling submission in the second quarter of 2026 and cites transformative Phase 3 DRAGON results; Belite is preparing commercialization teams for a potential launch next year, contingent on regulatory review.
Belite Bio (NASDAQ: BLTE) announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, was filed with the SEC on March 31, 2026 and is available on the company website.
Shareholders may request a free hard copy of the annual report. The notice was issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).
Belite Bio (NASDAQ: BLTE) will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. A live webcast is available via the company's investor relations Events page, with replays archived for 90 days.
Belite Bio (NASDAQ: BLTE) reported positive pivotal Phase 3 DRAGON topline results showing a 35.7% reduction in macular lesion growth versus placebo and remains on track to submit an NDA to the FDA in Q2 2026. The company completed a $402 million public offering and entered 2026 with $352.9M cash and $419.7M investments.
Other updates: DRAGON II reached targeted enrollment (72 subjects as of Feb 27, 2026), PHOENIX completed enrollment with 530 subjects, and GAAP net loss for 2025 was $77.6M.
Belite Bio (NASDAQ: BLTE) will host a live webcast on March 2, 2026 at 4:30 p.m. ET to discuss preliminary, unaudited fourth quarter and full year 2025 financial results and provide a business update.
According to the company, the webcast link is available at the events page and a replay will be accessible for approximately 90 days after the event.
Belite Bio (NASDAQ: BLTE) will participate at the 41st APAO Congress in Hong Kong, Feb 5-7, 2026, featuring oral presentations, a sponsored lunch symposium, and an exhibition booth.
Presentations include previously disclosed topline results from the Phase 3 DRAGON study of tinlarebant in adolescents with Stargardt disease type 1 and individual patient case reports.
Belite Bio (NASDAQ: BLTE) announced completion of enrollment in the Phase 2/3 DRAGON II trial of tinlarebant for Stargardt disease type 1 (STGD1). The global, 24-month, randomized, double-masked, placebo-controlled study enrolled 60 adolescent subjects (ages 12–20) across Japan, the United States, and the United Kingdom, including 15 Japanese subjects. Tinlarebant previously met the primary endpoint in the pivotal Phase 3 DRAGON trial with a 36% reduction in lesion growth (p=0.0033). Belite Bio said it remains on track to file a NDA with the FDA in 1H 2026 and designed DRAGON II to align with PMDA requirements to support potential approval in Japan.
Belite Bio (NASDAQ: BLTE) priced an underwritten public offering of 2,272,727 ADSs at $154.00 per ADS, with gross proceeds expected to be approximately $350.0 million before underwriting discounts, commissions and expenses. The company granted underwriters a 30-day option to purchase up to 340,909 additional ADSs. Closing is expected on or about December 3, 2025, subject to customary closing conditions.
Belite said it intends to use net proceeds for commercialization preparation, pipeline development and working capital. Joint active book-runners include Morgan Stanley, Leerink Partners, BofA Securities and Cantor; H.C. Wainwright is lead manager.